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The lack of phenylalanine 508 (∆F508 mutation) in the cystic fibrosis (CF) transmembrane
conductance regulator (CFTR) Cl− channel represents the most frequent cause of CF, a
genetic disease affecting multiple organs such as lung, pancreas, and liver. ∆F508 causes
instability and misfolding of CFTR protein leading to early degradation in the endoplasmic
reticulum and accelerated removal from the plasma membrane. Pharmacological correc-
tors of mutant CFTR protein have been identified by high-throughput screening of large
chemical libraries, by in silico docking of virtual compounds on CFTR structure models, or
by using compounds that affect the whole proteome (e.g., histone deacetylase inhibitors)
or a single CFTR-interacting protein. The presence of multiple defects of the CFTR pro-
tein caused by the ∆F508 mutation and the redundancy of quality control mechanisms
detecting ∆F508-CFTR as a defective protein impose a ceiling to the maximal effect that
a single compound (corrector) may obtain. Therefore, treatment of patients with the most
frequent CF mutation may require the optimized combination of two drugs having additive
or synergic effects.
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INTRODUCTION
Cystic fibrosis (CF), one of the most common inherited diseases
(∼1/3000 in Caucasian populations), is caused by mutations in the
CF transmembrane conductance regulator (CFTR) gene, which
encodes for a cAMP-regulated chloride channel expressed at the
apical surface of epithelial cells in the airways, intestine, pancreas,
and other organs. Defective Cl− secretion, arising from CFTR
mutations, causes a multi-organ disease. In the airways, impaired
mucociliary clearance favors recurrent bacterial infection and
severe lung damage.
The CFTR protein is composed of five distinct domains: two
membrane-spanning domains (MSD1 and MSD2), each having
six segments that completely cross the phospholipid bilayer and
contribute to the formation of the hydrophilic channel through
which anions are transported; two nucleotide-binding domains
(NBD1 and NBD2) that are exposed to the cytosol and participate
in ATP binding and hydrolysis; a regulatory domain (R) whose
phosphorylation regulates channel gating (Riordan, 2005).
The most frequent mutation among CF patients is the ∆F508
mutation, affecting a phenylalanine residue residing in NBD1. Its
frequency varies geographically, ranging from about 50% in south-
ern Europe to 70–90% in northern Europe and North America
(Bobadilla et al., 2002). Because of its high frequency and severity
it has a high priority as a therapeutic target.
Just a few years after the discovery in 1989 of the CF causative
gene, the∆F508 mutation was found to affect the expression and
function of the CFTR protein in different ways (Riordan, 2008).
The most severe defect consists of a strongly decreased ability
to mature and to traffic from the endoplasmic reticulum (ER)
to the plasma membrane (PM). The mutant protein is detected
by cell quality control (QC) mechanisms as being defective and
is degraded by the ubiquitin/proteasome system (Younger et al.,
2006; Riordan, 2008). However, it was also found that degrada-
tion of the ∆F508-CFTR protein can be reversed by incubating
cells at low temperature or with high concentrations of chemical
chaperons such as glycerol (Denning et al., 1992; Sato et al., 1996).
These experiments demonstrated that the trafficking defect asso-
ciated with the ∆F508 mutation is correctable, proof of concept
for the development of pharmacotherapy using small molecules
that correct the basic defect.
However, rescue by low temperature or overexpression also
revealed that∆F508 causes additional defects. First, electrophysio-
logical experiments, particularly patch-clamp recordings, showed
that channel activity is significantly reduced by the mutation
(Dalemans et al., 1991; Haws et al., 1996). Despite a strong ele-
vation in cytosolic cAMP (CFTR is physiologically activated by
cAMP-dependent phosphorylation),open channel probability was
approximately one-third of the wild-type protein (Haws et al.,
1996). Second, the ∆F508-CFTR protein has a reduced half-time
in the PM due to accelerated internalization and degradation
(Lukacs et al., 1993; Riordan, 2008).
This type of information evidenced the difficulty in rescuing
∆F508-CFTR expression and function because of the possible
requirement of multiple drugs to address the different defects. In
particular, it was found that maneuvers that were able to improve
trafficking did not affect the channel gating defect and vice versa.
Therefore, pharmacotherapy of ∆F508 probably has to be based
on the combination of two different types of drugs, generically
named corrector and potentiator, in order to address the trafficking
and gating defects respectively (Verkman and Galietta, 2009).
The search for CFTR potentiators has been particularly suc-
cessful. Campaigns of high-throughput screening and other
approaches have identified a plethora of active compounds (Verk-
man et al., 2006; Verkman and Galietta, 2009). Notably, CFTR
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potentiators not only increase the activity of ∆F508-CFTR but
also of other CFTR mutants with even more severe gating defects.
One of these potentiators, VX-770, identified by Vertex Pharma-
ceuticals (Van Goor et al., 2009) has been particularly successful in
clinical trials in patients with G551D (Ramsey et al., 2011), a muta-
tion characterized by very low channel activity but with normal
protein trafficking. The drug (named Kalydeco) has been recently
approved by the FDA to treat G551D patients.
The search for CFTR correctors has been more difficult and less
successful compared to that for potentiators. However, the good
results obtained with VX-770 demonstrates that pharmacotherapy
of the basic defect in CF is feasible. This represents a formidable
driving force for academic laboratories and industry involved in
the search of ∆F508 correctors. In the following sections we will
summarize the results obtained so far using different approaches
and define possible strategies for the future.
HIGH-THROUGHPUT SCREENING FOR∆F508 CORRECTORS
In the absence of indications about specific drug targets to rescue
∆F508-CFTR, the most promising and straightforward approach
was the screening of large small molecule libraries using functional
or biochemical assays. The rationale for this type of approach was
that the rescue of the mutant protein from the ER, resulting in
increased targeting to the PM (Figure 1), could be measured as
an increase in CFTR-dependent anion transport or by directly
detecting the CFTR protein on the cell surface with an antibody.
VERKMAN PROJECT
The first report on the identification of ∆F508- CFTR correctors
by screening a very large collection (150,000) of small molecules
was published in 2005 by Verkman and collaborators (Pedemonte
et al., 2005). The screening assay utilized Fischer rat thyroid (FRT)
epithelial cells co-expressing∆F508-CFTR and the yellow fluores-
cent protein (YFP) halide indicator YFP-H148Q/I152L in a 96-well
microplate format. FRT cells were first used by Sheppard et al.
(1994) to study CFTR function. Subsequently, we found that FRT
cells are highly useful to identify CFTR pharmacological mod-
ulators (Galietta et al., 2001; Zegarra-Moran et al., 2002). First,
untransfected FRT cells have negligible levels of anion transport.
Therefore, the activity of mutant CFTR after stable expression is
not contaminated by endogenous Cl− channels. Second, FRT cells
strongly attach to the cell culture support thus resisting all proce-
dures required by high-throughput screening (e.g., cell washings
and compound addition). Finally, FRT cells are suitable for a series
of electrophysiological assays such as short-circuit current and
patch-clamp recordings.
To identify correctors, FRT cells were incubated for 24 h with
compounds, washed, and then stimulated acutely with a cocktail
of a cAMP agonist plus genistein as a potentiator. CFTR activ-
ity in the cell membrane was calculated from the rate of YFP
fluorescence quenching caused by extracellular addition and there-
fore influx of iodide. The study led to the identification of five
classes of ∆F508-CFTR correctors (Pedemonte et al., 2005). In
particular, two classes of molecules appeared as the most inter-
esting. Class 4 correctors act by improving folding efficiency
and by stabilizing immature (core-glycosylated) ∆F508 protein.
It is reasonable to assume that the target of class 4 correctors
resides in the ER QC system. Instead, class 2 correctors increase
the residency time of the mutant protein in the PM, suggesting
that the mechanism of action involves the peripheral QC sys-
tem that targets ∆F508-CFTR toward lysosome-mediated degra-
dation. However, only class 4 correctors, in particular corr-4a,
showed efficacy on primary bronchial epithelial cells (Pedemonte
et al., 2005). The extent of rescue in these cells was relatively
small, with maximal CFTR activity being only 8% of that mea-
sured in non-CF cells. Further studies on class 2 compounds
identified a particular set, aminoarylthiazoles (AATs), with an
interesting dual activity. These compounds improve ∆F508 traf-
ficking as well as channel gating thus reducing the requirement
of a potentiator (Figure 1). Interestingly, the effect of AATs on
gating was not that of a classical potentiator since it required
several hours of treatment. Despite being effective in several
cell lines expressing ∆F508, AATs did not reach a significant
activity in primary bronchial epithelial cells (Pedemonte et al.,
2011).
VERTEX COMPOUNDS
In addition to the potentiator VX-770, Vertex Pharmaceuticals has
also obtained significant results in the discovery of correctors. The
company screened a library of 164,000 chemically diverse drug-
like compounds using a cell-based assay of membrane potential on
NIH-3T3 cells expressing ∆F508-CFTR (Van Goor et al., 2006).
The assay reports ∆F508-CFTR activity as a cAMP-stimulated
depolarization in the presence of a Cl− gradient. Screening iden-
tified 13 structurally distinct scaffolds with corrector activity, six
of which were also active on FRT cells with ∆F508-CFTR. The
mechanistic data obtained on the quinazolinone class (i.e., VRT-
325) suggest that the compounds act primarily or initially at the
level of the ER to facilitate the folding and export of ∆F508-
CFTR (Van Goor et al., 2006). More important, the subsequent
round of optimization of one of the hits from the primary screen-
ing led to the investigational drug VX-809 (Van Goor et al.,
2011). This compound appeared to be particularly effective in
primary cultures of bronchial epithelial cells from ∆F508 CF
patients. In combination with the potentiator VX-770, the cor-
rector elicited a 25% rescue. The efficacy shown in vitro, plus
the safety and tolerability in vivo, have allowed the advancement
of VX-809 into clinical trials. However, the efficacy of the drug
in vivo in ∆F508 patients (Clancy et al., 2012) is significantly
lower than that of the potentiator VX-770 in G551D patients
(Ramsey et al., 2011). For example, the lowering of chloride con-
centration in sweat, a good indicator of CFTR activity in vivo,
was 48 mM for VX-770 in G551D patients and 8 mM for VX-809
in ∆F508 patients. In contrast to the potentiator, the corrector
did not improve respiratory function or CFTR activity measured
by nasal potential recordings (Clancy et al., 2012). These results
highlight the particular difficulty in correcting the trafficking
defect of the ∆F508 mutation with respect to the gating defect
of G551D.
SILDENAFIL ANALOGS AND RDR1
Researchers at The McGill University identified novel CFTR
correctors from a library of 42,000 compounds, by means of a
biochemical high-throughput assay in a 96-well microplate format
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FIGURE 1 | Pharmacological rescue of ∆F508-CFTR. The activity of
∆F508-CFTR in the plasma membrane (PM) may be increased by long-term
treatment with a corrector, a small molecule that rescues ∆F508-CFTR from
the endoplasmic reticulum (ER) and/or increases the half-time of the protein
in the PM. The effect of a corrector can be evaluated at the functional level by
various technologies such as by directly measuring Cl− currents with
electrophysiological techniques (e.g., by short-circuit current recordings
shown in the Figure). CFTR activity is first triggered with a cAMP-elevating
agent (forskolin) and then further increased with a potentiator, a compound
that corrects the intrinsic channel gating defect caused by ∆F508. Finally, a
CFTR inhibitor is used to measure the total Cl− current dependent on CFTR.
Incubation with a corrector enhances the total current (middle trace) due to
the increase in the number of CFTR channels in the PM. A dual-acting
compound (bottom trace) not only increases the total current but also the
fraction of the current that is elicited cAMP alone thus minimizing the
requirement for a potentiator.
(Robert et al., 2008). Screening was performed using BHK cells,
which stably express ∆F508-CFTR bearing three tandem hemag-
glutinin (HA) epitope tags in the fourth extracellular loop after
amino acid 901. The appearance of ∆F508-CFTR or wild-type
CFTR at the cell surface was monitored in a plate reader with
an anti-HA antibody and a fluorescent secondary antibody. The
study led to the identification of different compounds, in par-
ticular the approved drug sildenafil, along with several structural
analogs with improved potency, having activity as ∆F508-CFTR
correctors. Later on, the same group developed a new assay, based
on differential scanning fluorimetry, to identify pharmacologi-
cal chaperones of ∆F508-CFTR, i.e., compounds that bind and
act directly on the mutated NBD1 domain of ∆F508-CFTR. The
hits derived from the previous cell-based screen for CFTR correc-
tors were tested by the authors, which identified one compound,
the phenylhydrazone RDR1, able to bind to and thermally sta-
bilize purified murine ∆F508-NBD1 in vitro (Sampson et al.,
2011).
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MPB COMPOUNDS
A small-scale screening for CFTR activators performed by
Becq et al. (1999) using iodide efflux experiments resulted
in the description of a class of tricyclic compounds called
benzo[c]quinoliziniums or MPB compounds. The compounds
MPB-07 and MPB-27 appeared as selective activators of wild-type
CFTR in different cell systems. Subsequently, synthesis of new
derivatives identified MPB-91 as a potent activator of G551D-
CFTR (Derand et al., 2001). Soon after, by studying the ∆F508-
CFTR activity and the trafficking by immunofluorescence in
freshly isolated native airway epithelial cells from CF patients,
the authors realized that treatment of cells with MPB-07 caused
dramatic relocation of ∆F508-CFTR to the apical region such
that the majority of CF cells showed a pattern similar to that of
non-CF cells (Dormer et al., 2001). Further studies demonstrated
that benzo[c]quinoliziniums selectively inhibit degradation of the
∆F508 protein, by protecting a proteolytic cleavage site by direct
binding to the first cytoplasmic domain of ∆F508-CFTR, thus
resulting in increased ∆F508-CFTR trafficking (Stratford et al.,
2003).
STRUCTURE-BASED CORRECTOR DESIGN
Although high-resolution structural information on full-length
CFTR protein is still missing, studies on the structure of CFTR
NBD1 and homologous ABC transporters has provided insights
into the three dimensional architecture of CFTR (Lewis et al., 2004,
2005; Rosenberg et al., 2011; Lukacs and Verkman, 2012). In native
CFTR, NBD1 interfaces with the cytoplasmic loops 4 (CL4) and
1 (CL1) in MSD2 and MSD1, while NBD2 associates with CL2
and CL3 of MSD1 and MSD2 respectively (Lukacs and Verkman,
2012). These interfaces not only transmit the ATP-dependent con-
formational changes occurring in NBDs to MSDs during channel
gating, but also play a crucial role in CFTR biogenesis (Lukacs and
Verkman, 2012). Indeed,∆F508 mutation destabilizes the confor-
mation of MSD1, MSD2, and NBD2, by impairing the assembly
of the interface between NBD1 and MSD2/MSD1, resulting in
protein misfolding (Lukacs and Verkman, 2012).
EPIX PROJECT
Starting from the structural information available for CFTR and
other ABC proteins, researchers at Epix Pharmaceuticals per-
formed an in silico structure-based screening for∆F508 correctors
utilizing homology models of CFTR (Kalid et al., 2010). After
modeling the intracellular region of CFTR, they identified three
cavities at inter-domain interfaces: (1) the interface between the
two NBDs; (2) the interface between NBD1 and CL4, in the region
of the F508 deletion; (3) the multi-domain interface between
NBD1 and 2 and CL1, 2, and 4. The working hypothesis was that
compounds binding at these interfaces may improve the stability
of the protein, potentially affecting the folding yield or surface
stability. In silico structure-based screening of a focused library of
∼100,000 compounds (extracted from the EPIX in-house database
containing ∼4-million unique compounds) highlighted 496 can-
didate compounds that were tested in functional assays. The study
resulted in the identification of 15 novel compounds of diverse
chemotypes, active as ∆F508 folding correctors. Interestingly, all
the binding sites subjected to screening yielded CFTR potentiators
as well as correctors. In addition, several of the chemical series
were found to harbor the potential for both types of activities,
with small chemical modifications independently modulating the
activity as corrector or potentiator. Notably, the study also led to
the identification of several compounds with a dual corrector-
potentiator activity (dual-acting). According to the authors, this
could be due to the fact that they used a CFTR model representing
the conducting state of the channel. Stabilizing this state by direct
binding of small molecules may increase the open probability of
the channel (potentiation), improve the stability of the protein
(potentially affecting the folding yield or surface stability of the
protein, i.e., correction), or both.
HYPOTHESIS-DRIVEN SEARCH FOR∆F508 CORRECTORS
The mechanisms of action of correctors have not been clarified,
and it is not known whether they interact directly with CFTR (i.e.,
acting as pharmacological chaperones) or with other intracellu-
lar proteins (Figure 2). However, considering the discrepancies
between their effects on heterologous expression systems versus
native epithelial cells from CF patients (Pedemonte et al., 2010),
it is reasonable to conclude that many correctors do not interact
directly with∆F508-CFTR to favor its folding and stabilization. If
that were the case, one would expect an activity that is indepen-
dent of cell background. Rather, it is probable that many correctors
modulate QC mechanisms responsible for mutant CFTR detec-
tion and degradation (i.e., they act as “proteostasis regulators”; see
Calamini et al., 2011).
Proteostasis regulators (Figure 2) are considered interesting
therapeutic agents to treat genetic diseases with protein misfold-
ing defects. Indeed, loss of proteostatic control has been implicated
in aging and in multiple disorders of protein misfolding, in which
the chronic expression and accumulation of misfolded, oxidized,
and aggregated proteins leads to cellular dysfunction. There is
increasing evidence that misfolded proteins expressed in diseases
of protein conformation are not efficiently counterbalanced by a
compensatory induction of cellular stress responses such as the
heat shock response and the unfolded protein response (Calamini
et al., 2011). Enhancing the activity or increasing the expression
of molecular chaperones through genetic techniques or pharma-
cological manipulation has been shown to restore proteostasis in
several disease models (Calamini et al., 2011).
MODULATION OF HISTONE ACETYLATION
Histone acetyl transferases (HATs) and deacetylases (HDACs) are
enzymes that mediate post-translational acetylation and deacety-
lation reactions, respectively, of histones, transcription factors, and
other cytosolic factors, leading to modulation of transcriptional
events during development and in response to environmental
changes (Hutt et al., 2010). Researchers at the Scripps Institute
(La Jolla, CA, USA), headed by William Balch, evaluated the effect
of knocking down single HDACs to address their specific roles in
human health and disease (Hutt et al., 2010). The study demon-
strated that HDAC7 suppression by siRNA-mediated silencing or
with the HDAC inhibitor SAHA, resulted in a substantial increase
in stabilization, trafficking, and activity of∆F508 cell surface chlo-
ride channel activity. The authors proposed that the mechanism
by which HDAC inhibition may ameliorate CF and possibly other
misfolding diseases involves the capacity to create an intracellular
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FIGURE 2 | Pharmacological chaperones vs. proteostasis regulators.
∆F508-CFTR rescue may be obtained by a pharmacological chaperone (PC)
that interacts directly with the mutant protein. For example, a PC may
increase the CFTR stability by improving the interaction between CFTR
domains. This effect would prevent the detection of ∆F508-CFTR by quality
control (QC) proteins thus allowing more protein in the plasma membrane
(PM). An alternative approach for ∆F508-CFTR is the use of a proteostasis
regulator (PR). These compounds act by globally changing the proteome, or a
more restricted group of proteins, to create an environment more benign
toward mutant CFTR.
environment that is more benign toward misfolded proteins (Hutt
et al., 2010). The efficacy of SAHA in primary airway epithelial
cells from ∆F508 patients has not been confirmed in other stud-
ies (Sondo et al., 2011; Van Goor et al., 2011). This may indicate
that the net balance of effects induced by HDAC inhibitors may
be significantly affected by experimental conditions.
MODULATION OF ER CALCIUM PUMPS
Experimental evidence suggests that inhibitors of ER calcium
pumps correct the ∆F508 trafficking defect through partial inhi-
bition of the interaction between ∆F508-CFTR and calnexin, a
ER lectin-like protein that binds monoglucosylated oligosaccha-
rides (Norez et al., 2006a). On this basis, Becq and colleagues
hypothesized that by inhibiting the deglucosylation of ∆F508
protein in the ER, glucosidase inhibitors may prevent the inter-
action of ∆F508-CFTR with calnexin and hence its entry into
the degradation pathway (Norez et al., 2006b). To verify this
hypothesis, the authors tested two compounds that inhibit ER α-
1,2-glucosidase, miglustat (an N -alkylated imino sugar also called
N -butyldeoxynojirimycin), and castanospermine, as well as an
inactive imino sugar analog (N -butyldeoxygalactonojirimycin).
The study demonstrated that miglustat rescues ∆F508-CFTR
in human and mice epithelial cells and prevents the interac-
tion of ∆F508-CFTR with calnexin in the ER, suggesting that
inhibition of deglucosylation of nascent proteins may be the
molecular mechanism of the compound’s effect (Norez et al.,
2006b).
LESSONS FROM BIOCHEMISTRY AND CELL BIOLOGY
The improved knowledge over the last few years of the molecu-
lar mechanisms involved in CFTR biosynthesis, trafficking, and
degradation is helping us understand the consequences of the
∆F508 mutation and the suitability of these mechanisms as ther-
apeutic targets (Lukacs and Verkman, 2012). First of all, it is clear
that∆F508-CFTR is scrutinized by multiple quality control check-
points both at the level of the ER and the PM. In particular, nascent
∆F508-CFTR is marked early on for degradation in the ER by the
ubiquitin ligase RMA1 in combination with Derlin-1 (Younger
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et al., 2006). At a later stage, when mutant CFTR is fully synthe-
sized, other proteins, such as the ubiquitin ligase CHIP, intervene
(Younger et al., 2006). Interestingly, a siRNA-based small scale
screening has revealed that CHIP and other proteins involved in
ER-associated degradation of CFTR are also important in periph-
eral QC and affect the half-time of mutant CFTR in the PM
(Okiyoneda et al., 2010). Therefore, there is a redundancy of mech-
anisms responsible for the detection of ∆F508-CFTR as a mutant
protein. Another aspect of ∆F508-CFTR is the possibility of traf-
ficking to the PM by an unconventional route. Under particular
conditions, such as incubation of cells at low temperature or block-
ade of ER-to-Golgi transport, ∆F508-CFTR may reach the cell
surface in a Golgi-independent way (Gee et al., 2011). The plethora
of QC and trafficking mechanisms associated with ∆F508-CFTR
explains the different observations reported in various studies. For
example, it has been repeatedly reported that the combination of
small molecules has additive or synergic effects on ∆F508-CFTR
rescue (Pedemonte et al., 2011). This kind of effect may also be
obtained by combining a corrector with the silencing of a QC pro-
tein. For example, treatment with corr-4a plus silencing of RMA1
led to a 13-fold increase in∆F508-CFTR maturation (Grove et al.,
2009). The additive/synergic effects of drug combinations clearly
point to different mechanisms of action. In fact, it was found that
corr-4a affects a step downstream of RMA1 (Grove et al., 2009).
Another consequence of QC redundancy is the sensitivity to cell
background. It is reasonable to hypothesize that the relevance of
some mechanisms may change from one cell type to another as
we have recently demonstrated (Pedemonte et al., 2011). This has
important practical implications: a corrector found by screening
in a given cell line may not be effective in another cell type and,
particularly, in primary airway epithelial cells.
Different studies indicate that the instability of ∆F508-CFTR
arises from two main characteristics: the intrinsic instability of
NBD1 and the defective docking of NBD1 to CL4. These results
point to two separate defects, both of which need to be corrected.
This requirement has been recently demonstrated in two indepen-
dent studies (Mendoza et al., 2012; Rabeh et al., 2012). High levels
of∆F508 rescue have been obtained only when suppressing muta-
tions have been introduced both in NBD1 and in CL4. The first
type of mutation, such as I539T or R555K, increases the stability of
NBD1. The second type of mutation, namely R1070W, improves
the interaction of NBD1 with CL4 by providing an aromatic group
that compensates for the lack of F508.
PERSPECTIVES
In conclusion, the increasing knowledge on ∆F508 is indicat-
ing that it may not be possible to fully correct the trafficking
defect with a single compound. Several in vitro studies point out
that a large rescue may be obtained only with a combination of
correctors. More effective correctors may be identified by high-
throughput screening of compounds with novel and unexplored
structure, by exploiting the increasing information available on
CFTR structure, or by taking advantage of the identification of
important proteins of the CFTR interactome. In this respect,
genome-wide siRNA screening could be very useful to identify
novel proteins with a high relevance for CFTR QC, trafficking, and
regulation. The possible need for two correctors to treat ∆F508
represents a problematic scenario in terms of drug development
and clinical testing. However, the concept of drug combination in
CF (e.g., a corrector plus a potentiator) is already accepted. The
use of two correctors instead of one potentiator and a corrector
may be justified if both compounds together elicit a high level of
CFTR function. In the near future, novel and effective treatments
for the CF basic defect are expected. These advances also represent
an important proof of concept and a paradigm for other genetic
diseases.
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